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ABSTRACT 
There is a current imperative to unravel the hierarchy of molecular pathways that drive the 
transition of early to established disease in rheumatoid arthritis (RA). Herein we report a 
comprehensive RNA-sequencing analysis of the molecular pathways that drive early RA 
progression in the disease tissue (synovium), comparing matched peripheral blood RNA-Seq 
in a large cohort of early treatment-naïve patients, the Pathobiology of Early Arthritis Cohort 
(PEAC). We developed a data exploration website (http://peac.hpc.qmul.ac.uk/) to dissect gene 
signatures across synovial and blood compartments, integrated with deep phenotypic profiling. 
We identified transcriptional subgroups in synovium linked to three distinct pathotypes, 
suggestive of divergent pathogenic pathways/activation disease states: fibroblastic pauci-
immune pathotype; macrophage rich diffuse-myeloid pathotype; and a lympho-myeloid 
pathotype characterised by infiltration of lymphocytes and myeloid cells. Pro-myeloid 
inflammatory synovial gene signatures correlated with clinical response to initial drug therapy, 
while plasma cell genes identified a poor prognosis subgroup with progressive structural 
damage. 
 
 
 
Key terms: rheumatoid arthritis; RNA sequencing; personalised medicine; synovial biopsy; 
ectopic lymphoid structures; lymphoid neogenesis; transcriptomics; Pathobiology of Early 
Arthritis Cohort study (PEAC)  
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INTRODUCTION 
The genetic architecture underlying susceptibility to rheumatoid arthritis (RA) (Eyre et al., 
2017) and its interaction with environmental and epigenetic factors has been characterised with 
increasing depth. While these predisposing factors initiate the start of RA, the subsequent 
aberrant biological processes and sequence of events, which drive the transition from systemic 
autoimmunity to joint inflammation, and from early to established disease, culminating in the 
development of synovitis and articular destruction, are less clear (Firestein and McInnes, 2017). 
Established RA displays clinical heterogeneity as demonstrated by variable prognosis, 
unpredictable propensity to rapid progression to structural damage and inconsistent response 
to therapy. Although RA treatment has been revolutionised by biologic and synthetic therapies 
targeting specific immune-mediated pathways, a significant number of patients fail to respond 
to current medications with only 20-30% reaching low disease activity status (as measured by 
70% improvement in ACR response criteria). Notably, treatment failure rates remain uniformly 
similar, regardless of the drug mechanism of action. The mechanistic reasons for such similar 
failure rates remain largely unknown, but the wide cellular and molecular variation described 
in the synovial tissue of patients with long-standing RA are likely to play a role in the variable 
treatment response and heterogeneous clinical evolution (Pitzalis et al., 2013). 
While a number of studies have examined synovial tissue gene expression (Badot et al., 
2009; Dennis et al., 2014; Lindberg et al., 2010; Timmer et al., 2007), few studies have focused 
on gene expression in early, treatment-naive RA (De Groof et al., 2016). Many of these studies 
have been performed in established/late stage disease and with a sampling bias due to major 
representation of large joints, while only a handful of studies have included small joints 
(Pitzalis et al., 2013). Furthermore, very few studies have to date reported a systematic 
molecular characterization by RNA-sequencing of the synovial tissue (Mandelin et al., 2018; 
Orange et al., 2018), but none in early treatment-naïve patients. Until now it has remained 
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unknown whether specific histological and transcriptomic findings represent an evolutionary 
response to longstanding joint inflammation following multiple immune-modulatory therapies, 
or embody distinct, essential RA pathogenetic mechanisms from disease onset. In addition, 
although microarray-based gene expression analyses have been performed in RA peripheral 
blood (Smith et al., 2013), no studies have examined coordinate gene expression changes at 
RNA-sequencing level in blood and synovium from the same patients. 
Here, we characterise at disease presentation early, pre-treatment RA (mean 5.6 months 
symptoms duration), using comprehensive RNA-seq analysis of synovial biopsies and blood 
from the largest biopsy-driven cohort of treatment-naïve patients: the Pathobiology of Early 
Arthritis Cohort (PEAC).  We combined RNA-seq with detailed synovial histology and 
correlated these molecular signatures with clinical and imaging phenotype data at disease 
presentation. We show that the spectrum of the synovial immune response is diverse and 
associated with differential blood immune signals. We identify transcriptional endotypes in the 
synovium linked to three distinct pathotypes: fibroblastic-rich pauci-immune pathotype, 
myeloid/macrophage-rich pathotype and lymphoid-rich pathotype with high plasma cell 
accumulation. This study yields major insights into pathogenic pathways in RA synovium and 
the links between local synovium and systemic immune responses in the blood, and 
demonstrates that synovial pathotype signatures are associated with diverse disease 
activity/severity and structural damage at baseline and response to DMARD therapy.  
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RESULTS 
Identification of distinct histological pathotypes in treatment-naive early rheumatoid 
arthritis synovium 
Ultrasound-guided synovial biopsies were selected from 90 consecutive individuals 
(demographics in Table S1) meeting the 1997 ACR classification criteria for early RA from 
the larger 355 Pathobiology of Early Arthritis Cohort (PEAC). At presentation, average clinical 
disease activity was high, with a mean DAS28-ESR score of 5.8 ± 1.3 (Table S1). Biopsies 
were obtained using a minimally invasive ultrasound-guided approach, which we pioneered on 
a large scale (Kelly et al., 2015) under local anaesthesia including both small/medium joint 
(~75%) and large joints (~25%) prior to any therapy with sDMARD including steroids. 
Synovial biopsies were analysed by immunohistochemistry and scored semi-quantitatively (0-
4) for presence of B cell aggregates (CD20+), plasma cells (CD138+), T cells (CD3+) and 
monocytes/macrophages (CD68+) in the synovial lining (CD68L) or sublining (CD68SL) 
layers (Figure 1A). Based on histology scores, synovial samples were classified as Lympho-
myeloid (CD20 B cell aggregate rich), Diffuse-Myeloid (CD68 rich in the lining/sublining 
layer but poor in B-cells) or Fibroid (paucity of immune-inflammatory cell infiltrate), as 
described in the Methods. 46 (51%) of biopsies were classed as Lympho-myeloid, 21 (23%) 
were Diffuse-Myeloid, 17 (19%) were pauci-immune Fibroid and 6 (7%) were unclassifiable 
by histological analysis due to low tissue quality following histology processing (Table S2). 
Whole tissue RNA-sequencing was performed on 90 synovial biopsies, pooling minimum six 
biopsies per patient. Three synovial RNA-seq samples were excluded following quality 
control, resulting in a post-QC sample size of 87 synovial RNA-seq samples. RNA-sequencing 
performed on matching peripheral blood samples was available on 67 individuals. 
 Histological pathotype, clinical parameters and ultrasound analysis were repeated after 
6 months, during which individuals were treated with DMARDs, predominantly methotrexate 
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in combination with sulfasalazine and/or hydroxychloroquine (Table S3). Sharp van der Heijde 
X-ray scores were measured at baseline and after 12 months of treatment. 
 
Cell-specific gene modules correlate with synovial cellularity by immunohistology 
confirming the presence of pathobiological endotypes in early RA synovitis   
We derived gene sets highly specific to immune cell tissue types (Table S4, Figure S1), based 
on CAGE sequencing data from the FANTOM5 project (Fantom Consortium et al., 2014), 
which correlates well with tissue-derived RNA-Seq (Yu et al., 2015). RNA-seq gene module 
scores specific for B cells, T cell subsets, monocyte/macrophage subsets, plasma cells and mast 
cells were analysed for correlation against relevant histological markers in synovial tissue. 
Gene module scores for CD19+ B cells, CD4+ T cells, CD14+CD16+ monocytes, plasma cells 
and mast cells correlated strongly with synovial histology scores for CD20 (r=0.65, 
P=3.8×10−11), CD3 (r=0.54, P=2.7×10−7), sublining CD68 (r=0.62, P=1.6×10−10), CD138 
(r=0.72, P=4.4×10−14) and CD117+ mast cells (r=0.51, P=1.3×10−5) respectively (Figure 1B). 
Hence cell-specific gene modules derived from FANTOM5 data enabled a new method to use 
RNA-seq data to reveal relative quantitation of tissue immune cell infiltration according to cell-
specific transcripts. Cell-specific module scores were compared between the Lympho-myeloid, 
Diffuse-Myeloid and pauci-immune Fibroid histological groups (Figure 1C): as expected, both 
the B cell and T cell gene scores were elevated in the Lympho-myeloid vs pauci-immune 
Fibroid group (P=8.7×10−7 and P=6.2×10−9 respectively). The CD14+CD16+ monocyte gene 
score was high in both Diffuse-Myeloid (P=1.6×10−4) and Lympho-myeloid (P=2.6×10−9) 
groups compared to the pauci-immune Fibroid group, while the CD138+ plasma cell score was 
highest in the Lympho-myeloid group (P=2.5×10−6). Thus, plasma cell, B cell, monocyte and 
synoviocyte RNA-seq cell specific modules were able to segregate the histologically defined 
Lympho-myeloid, Diffuse-Myeloid and pauci-immune Fibroid samples (Figure 1D). In plasma 
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cell-rich synovial samples, we also detected high monocyte/macrophage and T cell module 
scores (Figure 1D), suggesting a strong association with these cell types most likely to be 
connected to immunological priming of T cells by APC, leading to B cell activation and 
differentiation in the synovial tissue. Further analysis of a wider set of immune cell types using 
gene modules derived from FANTOM5 show more general patterns of immune cell infiltration 
in synovial tissue across the 3 major pathotypes (Figure 1E). Gene signatures of CD4+ T cell 
subsets including regulatory T cells, CD8+ T cells, plasmacytoid dendritic cells and NK cells 
were associated with the Lympho-myeloid group, while basophil, eosinophil and neutrophil 
signatures were more frequently observed in the Diffuse-Myeloid group. The pauci-immune 
Fibroid group showed increased magnitude of the synoviocyte gene module and, importantly, 
a distinct absence of immune cells (Figure 1E). Together, the distribution of cell lineage 
specific transcripts (Figure 1D, E) suggests that synovial tissue heterogeneity represents a 
divergent continuum with pauci-immune Fibroid samples, low on all types of immune-
inflammatory cells at one end of the spectrum; and Lympho-myeloid at the other end of the 
spectrum, with the full range of immune-inflammatory cells including macrophage, T, B and 
plasma cell infiltration; while the Diffuse-Myeloid samples show a prevalent macrophage 
infiltration, but largely lack T, B cell and plasma cell infiltration. 
 
Cell-specific gene modules in synovium correlate with clinical phenotypes featuring 
diverse disease activity and radiographic damage 
Correlation of clinical and radiographic parameters with cell-specific gene modules, showed 
that specific immune cell lineages associate with increased disease activity, reflected in the 28-
joint disease activity score (DAS28-ESR) including the sedimentation rate (ESR) and tender 
and swollen joints scores (Figure 2A). The plasma cell gene module showed strongest 
correlation with anti-CCP titre (r=0.30, FDR-adjusted P=0.0096) (Figure 2B), consistent with 
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previous studies linking synovial B cell infiltration and in situ plasma cell differentiation to 
anti-CCP antibody production (Corsiero et al., 2016; Humby et al., 2009; Teng et al., 2007). 
CD14+CD16− monocyte module correlated with pain visual analogue score (VAS) (r=0.38, 
Padj=7.6×10−4). Plasmacytoid dendritic cell (pDC) (r=0.41, Padj=3.5×10−4) and microvascular 
endothelial cell modules (r=0.35, Padj=0.0099) correlated with ESR, consistent with pDC 
involvement (in addition to mDC) in immune/inflammatory responses. Particularly strong 
correlation was seen between both biopsy joint synovial thickness and power Doppler 
ultrasonographic measures with gene expression modules, confirming that gene expression of 
cellular infiltration strongly matches imaging signs of active joint inflammation in the 
particular joint undergoing biopsy. The plasma cell gene module was the strongest predictor of 
ultrasonographic synovial thickness (r=0.56, Padj=7.1×10−7) and power Doppler signal (r=0.44, 
Padj=2.1×10−4) (Figure 2C), consistent also with a strong correlation between CD138+ histology 
score and ultrasonography (Figure S2). In contrast, there was an inverse correlation between 
ultrasound scores and synoviocyte gene expression (pauci-immune Fibroid pathotype). Several 
cell type modules showed significant correlation with radiographic damage as measured by 
baseline total Sharp van der Heijde score (Figure 2D): B cell (r=0.31, Padj=0.015), CD4+ 
memory T cell (r=0.30, Padj=0.018), regulatory T cell (r=0.28, Padj=0.029) and plasma cell 
(r=0.28, Padj=0.025) gene signatures were correlated with radiographic change. These data 
suggest that infiltration of multiple immune cell types associated with ectopic lymphoid 
responses in the synovial tissue may be linked to more destructive disease from early on in the 
course of RA. 
 
Synovium and blood RNA-seq comparison reveals differential axes of gene expression 
We next compared gene expression in synovium and peripheral blood in the three histologically 
identified subgroups using FDR adjusted likelihood ratio test and pairwise group tests for 
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differential expression. Differentially expressed genes were initially visualised using standard 
volcano plots (Figure S3). However due to the three-way nature of the analysis, the multiple 
pairwise comparisons rendered data interpretation difficult. Hence, we developed a 3D volcano 
plot using a cylindrical geometry to aid visualisation and interpretation of the three-way group 
comparison (Figure 3A, B, Movie S1, S2). The 3-way volcano plots demonstrate that the 
largest groups of differentially expressed RA synovium genes are upregulated in the Lympho-
myeloid group alone (blue) or Diffuse-Myeloid and pauci-immune Fibroid combined (yellow), 
with a smaller number of genes associated with Diffuse-Myeloid group alone (red) (Figure 
3A). The polar angle of each gene directly conveys the degree to which a gene is associated 
with one or more pathotypes. Fold change can be used as an alternative to Z score for the radial 
scale (see online http://peac.hpc.qmul.ac.uk). 
 Comparison of synovium and blood RNA-seq showed a stark difference in the absolute 
quantity of differentially expressed transcripts between pathotypes, with approximately 3000 
transcripts in synovium compared to only eight differentially expressed transcripts in matched 
peripheral blood at FDR<0.05 (Figure 3B). The eight differentially expressed blood transcripts 
were associated with the Lympho-myeloid pathotype, and seven out of eight are known type I 
interferon response genes (IFI27, ISG15, IFI44L, OASL, USP18, RSAD2 and LY6E). The 
overall transcriptome shape as visualised in the polar plots (Figure 3A,B) showed greater whole 
transcriptome variation between the Lymphoid-Fibroid axis in synovium in comparison to the 
Myeloid-Fibroid axis in blood. Pairwise volcano plots (Figure S3) confirmed the largest 
number of differentially expressed genes in peripheral blood were seen in the Myeloid-Fibroid 
comparison, but in contrast in synovium the Myeloid-Fibroid comparison showed the fewest 
number of differentially expressed genes. 
 To facilitate the interrogation of this unique large synovial tissue RNA-seq database, 
we developed a web interface (http://peac.hpc.qmul.ac.uk/) that facilitates visualisation and 
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exploration of the data (Figure S4). The web interface includes an interactive version of the 3D 
volcano plot; an interactive interface for comparing genes or gene modules of interest in 
synovium or blood against histological, clinical or radiographic measures; and searchable 
tables of differentially expressed genes and module comparisons. 
 To find evidence of natural structure in the transcriptome data, principal component 
analysis (PCA) of synovium was compared with whole blood (Figure 3C,D). Synovial 
transcriptome PCA showed clear separation between Lympho-myeloid and pauci-immune 
Fibroid groups while the Diffuse-Myeloid partially overlapped with the two groups. However, 
in whole blood transcriptome, PCA showed separation between patients showing a Diffuse-
Myeloid and pauci-immune Fibroid synovial pathotype on PC1, while patients with the 
Lympho-myeloid synovial pathotype were evenly distributed. Taken together, the clustering 
analysis and PCA suggest that, while the synovium gives clean delineation of the Lympho-
myeloid group, particularly in those individuals with synovial plasma cells, the blood 
transcriptome shows significantly less differentiation between pathotypes. 
 
Synovial RNA-Seq gene clusters delineate pathways characterising histo-pathotype 
spectrum 
Differentially expressed genes in RA synovial biopsies were subjected to unsupervised 
hierarchical clustering and compared against histology (Figure 4A). Cluster S1 and S2 were 
mainly associated with Pauci-immune and Diffuse-Myeloid samples, while S3 and S4 were 
typically associated with more inflamed Diffuse-Myeloid or Lympho-myeloid samples. In 
comparison, little evidence of structure and relationship to pathotypes was observed in 
clustering of the top ~500 variable genes in blood (data not shown). Biological processes for 
each synovial and blood gene cluster were investigated using Ingenuity Pathway Analysis 
(IPA) (Figure 4B). Overall pathway analysis showed strong segregation, concordant with 
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histology. The strongest pathway enrichment was identified in cluster S4 (lympho-myeloid 
group), which were associated with both B-cell, plasma-cell and macrophage infiltration 
histologically, and demonstrated multiple immune cell activation, encompassing B and T 
helper cell maturation associated with dendritic cell activation, antigen presentation and 
interaction with NK-cells typically associated with ectopic lymphoid-like structure (ELS) 
formation. Cluster S3 pathways showed specific pro-inflammatory pathways including 
phospholipase C, PI3K and NFAT signaling, known to be important drivers of activation and 
infiltration of tissue neutrophils, macrophages and other immune cell types into inflamed 
synovium (Jakus et al., 2009). In contrast, clusters S1 and S2, which were dominated by pauci-
immune and diffuse myeloid samples, were associated with pro-fibroblast Wnt/β-catenin 
pathways, while immune/inflammatory pathways were notably lower. 
 
Modular analysis shows discordance between blood and synovium immunological 
pathways 
Blood transcript modules (Li et al., 2014) were applied to the RA synovium and peripheral 
blood transcriptome data. We used QuSAGE methodology to compare differential gene 
module expression between synovial pathotypes in synovium (Figure 5A and S5A) and 
peripheral blood (Figure 5B and S5B). In synovium, plasma cell, B and T cell gene modules 
were strongly upregulated in the Lympho-myeloid pathotype, as were gene modules for CD28 
costimulation, IL7 and B and T cell differentiation (Figure 5A, S5A). Proinflammatory 
chemokine and cytokine modules and dendritic cell modules were associated with both 
Diffuse-Myeloid and Lympho-myeloid pathotypes, in keeping with their role in monocyte 
recruitment and macrophage activation in the Diffuse-Myeloid pathotype, and ectopic 
lymphoid structure development in the Lympho-myeloid pathotype. Pauci-immune Fibroid 
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synovial modules were enriched for cell junction, cell-cell adhesion, extracellular matrix and 
Hox cluster consistent with fibroblast and connective tissue development. 
 To complement this analysis, we performed weighted correlation network analysis 
(WGCNA) on synovium RNA-seq. Synovium WGCNA modules (Figure 5C and Table S5) 
were annotated against 13 cell populations observed in single cell RNA-seq of RA synovium 
(Stephenson et al., 2018), by testing for module gene enrichment in genes upregulated in each 
cell type by hypergeometric test. Correlation of synovium WGCNA modules with clinical 
variables showed comparable results to FANTOM5 cell-lineage modules (Figure S6 and see 
website), and provides additional information on synovial cell types not available in 
FANTOM5, including synovial fibroblast subtypes (Mizoguchi et al., 2018), synovial 
macrophage and T cell subpopulations including peripheral helper T cells (TPH cells) (Rao et 
al., 2017). The single cell plasma cell module showed similar results to FANTOM5 (Figure 
S6A). The SC160 module, which contains multiple genes associated with PD-1high TPH cells 
including PDCD1, TIGIT and CXCR6, showed strong correlation with increased disease 
severity measured by DAS28-ESR, ultrasound at the biopsy joint and Sharp van der Heijde 
radiographic damage score (Figure S6B). A CD55+ type 1 fibroblast associated module, 
SC210, was strongly associated with the pauci-immune Fibroid pathotype, and was inversely 
correlated with inflammatory cell histology, and showed inverse correlation with disease 
severity measured by multiple clinic-radiographic parameters (Figure S6C). 
 Heatmaps of individual gene modules revealed that plasma cell associated genes such 
as CD27 and IGLL5 were strongly upregulated in Lympho-myeloid samples, while multiple 
chemokine genes were increased in both Lympho-myeloid and Diffuse-Myeloid samples 
(Figure 5D,E). In contrast, Wnt signalling module M206 (Figure 5D,E), containing FRZB, 
which has a critical role in bone and cartilage development, was elevated in the pauci-immune 
Fibroid pathotype (Figure 5D,E). 
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The polar plot of the blood module signatures (Figure 5B) was distinctively different 
from synovium with the main axis of variation lying from Myeloid to Fibroid, mirroring the 
distinct whole transcriptome variation between the two compartments (Figure 3A,B polar 
plots). Noteworthy blood module associations with pathotype included type I interferon 
response and paradoxical changes in the B cell compartment. Increased peripheral blood type 
I interferon response (M127), which is involved in terminal B cell maturation and plasma cell 
development, was associated with the Lympho-myeloid pathotype in synovium (Padj=0.002) 
(Figure 5B, E and S5B), in line with our earlier differential expression data (Figure 3B). Blood 
B cell modules were reduced in the Diffuse-Myeloid pathotype, which could represent B cell 
flux into tissues leading to reduced circulating peripheral B cells (Figure 5E). 
We directly compared differences between synovium and blood, looking at the number 
of gene modules in each compartment which significantly correlated with histology, clinical 
and radiological variables at FDR<0.05 (Figure 5F). Synovial modules were strongly 
correlated with histology, acute phase response, visual analogue pain score (VAS) and overall 
disease activity measured by DAS28-ESR/CRP. Synovium modules also strongly correlated 
with ultrasound power Doppler and synovial thickness at the biopsy joint. Blood module 
associations with clinical parameters were generally rarer than for synovium, except for strong 
correlation with blood markers of acute phase response such as ESR and CRP. Looking 
specifically at disease activity measured by DAS28-CRP (Figure 5G), substantially more 
synovium modules correlated with DAS28-CRP than for blood, however a few monocyte and 
dendritic cell modules such as M81, M168 and toll-like receptor (TLR) module M16 showed 
correlation with DAS28-CRP in both synovium and blood. 
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Synovium plasma cell gene expression is associated with anti-CCP antibody positivity and 
predicts worse prognosis at 12 months 
Differential gene expression between anti-CCP antibody (ACPA) positive and ACPA negative 
individuals showed increased plasma cell genes such as XBP1, ODC1 and EAF2 as well as 
LAMP5, a regulator of TLR9 in plasmacytoid dendritic cells (Combes et al., 2017), which was 
the strongest pro-Lympho-myeloid pathotype gene (Figure 6A). In contrast, although relatively 
few genes were differentially expressed in blood between ACPA positive/negative individuals, 
these included type I interferon response genes IFI44L and IFI27 (Figure S7), consistent with 
a blood type I interferon signature underlying synovial plasma cell infiltration. RA individuals 
with x-rays at baseline and 12-month follow-up were divided into progressors, in whom 
radiographic bone erosions had worsened over 12 months, or non-progressors. Plasma cell 
associated genes were significantly increased in bone erosion progressors compared to non-
progressors, demonstrating that synovial plasma cell gene expression at baseline predicts a 
worse prognosis radiographically at 12 months. Single cell RNA-seq-annotated WGCNA 
modular analysis showed that ACPA positivity was associated with increased plasma cell and 
macrophage gene modules (Figure 6C), and baseline plasma cell modules also predicted bone 
erosion progression at 12 months (Figure 6D). 
 
Transcriptional regulators of ectopic lymphoid structure development 
Upstream regulator analysis using Ingenuity pathway analysis (Figure 6E) showed that key 
regulators including IFN-g, IFN-a2, IFN-β1, IL7, IL21 and CD40L were associated with the 
Lympho-myeloid pathotype, consistent with the dominant theme of B cell proliferation, 
differentiation and plasma cell development (Hiepe et al., 2011) and the previously reported 
association of IL-7 pathway with synovial B cell infiltration (Badot et al., 2009; Timmer et al., 
2007). The follicular helper T cell cytokine IL-21 is important for ELS maturation (Jones et 
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al., 2015; Jungel et al., 2004; Liu et al., 2015). We also confirmed the association of the 
chemokine CXCL12 with ELS formation (Timmer et al., 2007), consistent with its role in 
maintaining long-lived plasma cells (Tokoyoda et al., 2004). TNF, IFN-g, IL-1β, IL-4, IL-6 
and IL-15 were upstream regulators for the diffuse Myeloid pathotype, while WNT3A was an 
upstream regulator of the pauci-immune Fibroid pathotype. 
 Histological pathotype was re-analysed after 6 months (Figure 6F), during which 
individuals were treated with DMARDs (Table S3). In ACPA positive RA individuals, the 
histological pathotype showed a more consistent tendency (P=0.020) to change to a less 
inflammatory pathotype, i.e. from lymphoid to myeloid, or myeloid to fibroid (Figure 6G), 
whereas in ACPA negative individuals change in pathotype at 6 months was less consistent 
(P=0.27). Stratifying DAS28-ESR measurements according to whether individuals had shifted 
to a more or less inflammatory pathotype from baseline to 6 months, we observed a linear 
relationship between shift in pathotype and change in DAS28-ESR (r=0.31, P=0.0027) (Figure 
6H). Thus, individuals, whose pathotype shifted to a less inflammatory pathotype at 6 months, 
e.g. from lymphoid to myeloid or lymphoid to fibroid, showed significantly greater reductions 
in DAS28-ESR, whereas individuals whose pathotype became more inflammatory, e.g. from 
fibroid to myeloid, on average showed no reduction in disease activity. Thus, changes in 
synovial pathotype, as detected by serial synovial biopsy, reflect clinical responsiveness to 
DMARD therapy. This is consistent with our assertion that the complex autoimmune milieu 
observed within RA synovial tissue directly underlies core pathogenic processes which drive 
RA progression, and when improved therapeutically, the change in this autoimmune milieu is 
detectable in sequential biopsies. 
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Baseline predictors of response to treatment 
Numerous synovial modules correlated with response to treatment after six months measured 
by change in DAS28-CRP, including type I interferon signature/ antiviral modules, monocyte 
and chemokine modules, dendritic cell and antigen presentation modules, and B cell modules 
(Figure 7A,C), demonstrating that a more inflammatory synovial phenotype at baseline 
correlated with a greater fall in DAS28-CRP after 6 months of DMARD treatment. However, 
no blood modules were associated with clinical response. Looking at the acute phase response 
(Figure 7B), we observed that both synovium and blood modules were associated with 
reduction in ESR, with some modules such as TLR signalling, antiviral response and dendritic 
cell modules showing association with ∆ESR in both compartments (Figure 7B,D,E). In 
contrast, pauci-immune Fibroid associated Hox cluster modules were associated with 
resistance to treatment. These findings suggest that while blood gene expression directly 
reflects the systemic inflammatory and acute phase response, and thus is associated with 
change in ESR or CRP following treatment, blood gene expression is not a strong predictor of 
overall clinical response. Grouping patients by EULAR response using DAS28-CRP, we 
observed that modules for CD8+ T cells, mast cells and TLR signalling were significantly 
increased in EULAR moderate/good responders at 6 months compared to non-responders, 
whereas a CD55+ type 1 fibroblast module was lower in responders (Figure 7F), although 
pathotype per se was not significantly different between EULAR response groups. Thus, 
specific synovial cell types are associated with differential response to DMARD treatment.  
 
Discussion 
This study represents the most comprehensive exploration of synovial and blood RNA-Seq in 
rheumatoid arthritis to date, which combines detailed histopathological classification and in-
depth clinical phenotyping. The interactive website (http://peac.hpc.qmul.ac.uk/) developed 
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with this data will allow the research community to dissect synovial pathology architecture, 
allowing researchers to explore the data and correlate genes and gene modules with 
histological, clinical and radiographic parameters. Based on our previous work using 
histopathology, we identified three partially overlapping groups: (1) a Lympho-myeloid (L) 
group showing aggregates of B and T lymphocytes associated with diverse inflammatory cell 
infiltrate, (2) a Diffuse-Myeloid (M) group characterised by macrophage/monocyte 
enrichment, but poor in B cells and (3) a pauci-immune Fibroid (F) group showing a distinct 
lack of immune-inflammatory infiltrate. Multiple techniques were employed to investigate 
links between synovium and blood transcriptomes to further define the pathobiological 
subtypes. 
 We developed and validated cell-lineage specific gene modules derived from 
FANTOM5 data for relative quantitation of cell populations in RNA-seq tissue samples. This 
transcript-based immune cell phenotyping performed well in comparison to established 
immunohistology (Humby et al., 2009). The analysis suggested that the immune cell infiltration 
in synovium is a continuum with pauci-immune Fibroid pathotype, lacking immune cell 
infiltration at one end, and the Lympho-myeloid pathotype with diverse immune cell 
infiltration with NK cells and plasmacytoid DC, with fully formed ELS and high levels of 
plasma cells at the most advanced end of the spectrum. Macrophage infiltration appeared to be 
a prerequisite for B cell activation and plasma cell development, implying their potential for 
local differentiation into antigen presenting cells (APC) driving T cell activation, Tfh activation 
and formation of ELS. Although our data support the notion that the pathotypes represent 
different types of synovitis, with differing pathogenic process and inflammatory milieu, we 
cannot exclude the possibility that they represent evolving states of activation or gear shifts in 
the disease process. 
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Correlation of cell-specific RNA-seq gene modules with clinical and radiological 
parameters showed that the multiple synovial immune cell types including 
monocytes/macrophages were correlated with disease activity measured by DAS28-ESR. The 
plasma cell gene module correlated with anti-CCP antibody and rheumatoid factor titre, 
consistent with the notion that local in situ plasma cell differentiation and perpetuation are 
associated with high anti-CCP antibody titre in RA (Corsiero et al., 2016; Teng et al., 2007). 
Multiple cell modules were correlated with ultrasonographic scores at the biopsy joint, with 
particularly strong correlation for the plasma cell transcript module, but inverse correlation 
with the synoviocyte module. Similarly, radiographic joint damage at baseline correlated with 
CD4+ T cells, Treg, B cells and plasma cells. Historically, previous studies identified an 
association between synovial macrophage infiltration and radiographic progression (Bresnihan 
et al., 2009; Yanni et al., 1994). In our study, gene transcript changes in synovium largely 
reflect the altered cellularity in synovium in line with pathogenic processes in RA. The data 
suggest that disease severity, as measured by ultrasonographic and radiographic change, 
correlates with advanced synovial immune cell infiltration and in situ plasma cell development. 
Recent RNA-Seq studies of synovium in established, longstanding RA have identified 
novel cell populations including PD-1 high peripheral helper T cells (Rao et al., 2017) and 
distinct fibroblast subsets (Mizoguchi et al., 2018). As counterpart to using FANTOM5, we 
leveraged single cell RNA-seq data to annotate WGCNA synovial gene modules according to 
13 cell populations identified in single cell RNA-seq of RA synovium (Stephenson et al., 2018). 
The single cell RNA-seq annotated gene modules showed comparable results to the 
FANTOM5 approach, and add additional information about other important synovial cell types 
not available in FANTOM5, including fibroblast, macrophage and T cell subpopulations 
(Figure 5C). Although single-cell RNA-seq of synovial biopsies would have allowed more 
complete gene expression deconvolution at the level of individual cells, this approach would 
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have been difficult to apply to large numbers of samples, and the reduced dynamic range of 
single cell RNA-seq impairs quantitation of rare, low abundance transcripts. In the future, 
ongoing efforts in collaboration with the NIH-funded Accelerating Medicines Partnership 
(AMP) combining both methodologies may yield further insights.  
Synovial RNA-seq data demonstrated distinct gene clustering with significantly 
different gene sets up-regulated between the three pathological groups. We developed an 
interactive 3D volcano plot, as part of our website resource (http://peac.hpc.qmul.ac.uk/), to 
illustrate the three-way differences in synovial gene expression. Differential gene expression 
in blood was far less extensive than in synovium, but revealed type I interferon response genes 
associated with the presence of the Lympho-myeloid pathotype in synovium. Similar type I 
interferon response genes have been associated with differential response to Rituximab 
(Raterman et al., 2012; Vosslamber et al., 2011). Synovium and blood compartments 
demonstrated differential axes of gene expression variation. Synovium gene expression 
showed strongest delineation along the Lymphoid-Fibroid axis, while blood whole 
transcriptome showed a tendency to delineate pauci-immune Fibroid from Diffuse-Myeloid 
development. A potential implication is that the adaptive immune response is localised to the 
site of inflammation or secondary lymphoid organs. Secondary amplification of the myeloid 
system via cytokines such as type I IFN may lead to a signature in the blood. Cluster analysis 
of pathotype-specific genes identified pro-inflammatory genes common to both the Lympho-
myeloid and Diffuse-Myeloid groups with pathways consistent with infiltration and 
differentiation of multiple cell types, including T helper cells and dendritic cells, while genes 
which were more specific to B cell differentiation including PI3K signalling were associated 
with B cell/ plasma cell infiltration histologically. 
We did not perform simultaneous biopsies of different joints in the same patient, so we 
cannot address the question of how stable synovial histology and RNA expression are between 
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joints within the same patient. However, other studies support the notion of stable cellular 
infiltrates (Kraan et al., 2002) and T cell clonality (Musters et al., 2018) between joints. 
Synovial histology and RNA expression directly reflect the inflammatory state within the 
biopsied joint, so our finding that specific immunological processes in peripheral blood such 
as the type I interferon response were associated with synovial B cell infiltration, supports the 
notion of the RA disease process driving a consistent immunological response in each tissue 
compartment. 
Baseline synovial plasma cell gene modules were associated with ACPA positivity and 
worse prognosis in terms of radiographic damage at 12 months (Figure 6). Local in situ plasma 
cell differentiation and persistence of long-lived tissue plasma cells are likely to play an 
important role in anti-CCP antibody formation and perpetuation of disease. Upstream regulator 
analysis (Figure 6E) identified multiple regulators known to facilitate ectopic lymphoid 
structure development within tissues, consistent with local B cell maturation and plasma cell 
differentiation being key events underlying the Lympho-Myeloid pathotype. 
Following treatment with DMARDs, shift in synovial pathotype on repeat biopsy at 6 
months correlated with clinical response to DMARD therapy (Figure 6F-H). Individuals, 
whose pathotype became less inflammatory (e.g. lymphoid to myeloid, or lymphoid to fibroid), 
showed greater reduction in disease activity, while individuals whose pathotype progressed to 
a more inflammatory state showed little or no response. We observed that high baseline 
inflammatory synovial gene modules including TLR signalling, type I IFN signature, and 
macrophage chemokine modules were associated with better response at 6 months to 
DMARDs, assessed by ∆DAS28-CRP, whereas blood modules were only associated with 
reduction in ESR at 6 months. Thus, baseline blood gene expression can to a limited extend 
anticipate changes in the systemic acute phase response in response to DMARD therapy, but 
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are less informative than synovium gene expression for predicting clinical outcome which 
includes swollen/tender joint count and VAS. 
Although disease heterogeneity has long been postulated in RA, our study provides the 
clearest map to date of the relationship between peripheral blood signals and development of 
different patterns in the synovium early in the RA disease process prior to therapeutic 
intervention, while avoiding the confounding effects of therapy, especially corticosteroids, on 
disease tissue pathology. Our data advances our understanding of RA pathogenesis, revealing 
major differences in synovial gene expression across the histo-pathotype spectrum, and 
identifying associated pathways/gene modules for each pathotype. Although there was 
substantially less variation in the peripheral blood transcriptome than in synovium, a few 
identifiable blood transcript signals were linked to clinical measures of disease activity 
(monocyte activation and TLR signalling). While synovium, both histologically and at the gene 
expression level, was highly informative for its association with disease activity and disease 
progression, blood gene expression independently revealed systemically altered gene 
expression in the form of upregulated type I interferon signature linked to pathogenic plasma 
cell infiltration into synovium. Overall, synovial modules were superior for predicting clinical 
response to DMARD therapy at 6 months and poor prognosis in terms of radiographic 
progression at 12 months. 
 In summary, we report an in-depth RNA-sequencing analysis of synovial tissue and 
peripheral blood in early rheumatoid arthritis, prior to therapeutic modification of the disease 
pathology, linked to detailed phenotypic profiling. Our data suggests that persistent synovial 
plasma cell infiltration identifies individuals at increased risk of rapid disease progression and 
severe joint destruction, and provides the strongest evidence yet that optimal stratification of 
RA therapies would be enhanced by sampling of both synovium and blood biomarkers.  
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Figure Legends 
 
Figure 1. Synovium RNA-sequencing correlates with histological pathotype in early 
rheumatoid arthritis 
(A) Immunohistochemistry of synovial biopsies for CD20+ B cells, CD3+ T cells, CD68+ 
macrophages in synovial lining/sublining layers and CD138+ plasma cells from treatment-
naive individuals with early rheumatoid arthritis. Synovial biopsies were categorised as 
Lympho-myeloid (B cell aggregates present), Diffuse-Myeloid (sublining macrophage 
infiltration), or pauci-immune Fibroid (lack/low inflammatory cell infiltrate). (B) Comparison 
of cell-specific RNA-seq gene module scores with histology scores. (C) Cell-specific gene 
scores compared across histology pathotypes. Statistical analysis by one-way ANOVA with 
Bonferroni post-test. (D) Clustering of Lympho-myeloid, Diffuse-Myeloid and pauci-immune 
Fibroid samples according to B cell, monocyte and synoviocyte RNA-seq modules. (E) 
Heatmap showing hierarchical clustering of cell-specific gene module scores and collapsed 
module space (right) highlighting cellular composition of synovial biopsies from each 
pathotype. 
 
Figure 2. Clinico-radiographic correlates of cell-specific gene modules in rheumatoid 
arthritis synovium 
(A) Correlation heatmap showing Spearman correlation of cell-specific gene modules against 
baseline clinical (ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CCP, anti-
cyclic citrullinated peptide antibody titre; RF, rheumatoid factor titre; VAS, visual analogue 
score; HAQ, health assessment questionnaire), ultrasonographic scores (ST, synovial 
thickness; PD, power doppler) at the biopsy joint (Ultrasound ST/PD BJ) or across 12 
representative joints (Ultrasound ST/PD 12) and radiographic parameters (Total Sharp van 
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der Heijde score). (B) Boxplots of clinical parameters by tertile demonstrating correlation 
with cell-specific gene modules. (C) Linear regression of ultrasound biopsy joint parameters 
against cell-specific gene modules. (D) Boxplots of Total Sharp van der Heijde radiographic 
score by tertile correlated with cell-specific gene modules. P values were calculated by linear 
regression models. 
 
Figure 3. Synovium and blood RNA-seq comparison reveals differential axes of gene 
expression 
(A, B) 3D cylindrical volcano plots of differentially expressed genes comparing RNA-
sequencing of (A) synovial tissue and (B) whole blood. Vectors for pathotype mean Z score 
per gene were projected onto a polar coordinate space analogous to RGB (red-green-blue) 
colour space mapping to HSV (hue-saturation-value) as described in the Methods. Lympho-
myeloid, Diffuse-Myeloid, pauci-immune Fibroid vectors are mapped to 3 axes L, M, F using 
polar coordinates in the horizontal plane. z axis shows –log10 P value for likelihood ratio test. 
Genes with adjusted P value for likelihood ratio test <0.05 (z axis) were considered 
significant (non-significant genes coloured grey). Colours demonstrate pairwise comparisons 
(FDR<0.05) between the 3 histological pathotypes: primary colours denote upregulation in 
one group only for Lympho-myeloid (blue), Diffuse-Myeloid (red) and pauci-immune 
Fibroid (green) compared to reference group with minimum gene expression; composite 
colours show genes significantly upregulated in two groups (Myeloid+Lymphoid, purple; 
Fibroid+Myeloid, yellow; Lymphoid+Fibroid, cyan). Lateral view and 2D polar plots are 
shown below. (C, D) Principal component analysis of whole transcriptome RNA-seq data 
from untreated rheumatoid arthritis (C) synovium and (D) whole blood, showing separation 
of Lympho-myeloid (blue) and pauci-immune Fibroid (green) histological pathotypes on 
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principal component 1 (PC1) for synovial RNA-seq, with separation of Diffuse-Myeloid (red) 
and pauci-immune Fibroid samples on PC1 in whole blood. 
 
Figure 4. Clustering and pathway analysis of differentially expressed genes in 
rheumatoid arthritis synovium 
(A) Heatmap of 2964 RNA-seq genes differentially expressed between three histological 
pathotypes (Lympho-myeloid, Diffuse-Myeloid, pauci-immune Fibroid) (FDR<0.05, n=87). 
Upper tracks show histological scores for CD3, CD20, CD68L, CD68SL and CD138 and 
overall pathotype. Unsupervised hierarchical clustering demonstrated clustering of genes into 
four clusters demonstrating some overlap between the three histologically determined 
pathotypes. (B) Ingenuity pathway analysis performed on synovial gene clusters produced by 
hierarchical clustering identified pathways by gene enrichment, using whole genome as 
background. Cluster S1, S2 represent pauci-immune Fibroid/Diffuse-Myeloid samples, 
cluster S3-4 represent Lympho-myeloid/Diffuse-Myeloid samples. Colour scale and numbers 
depict –log10 FDR adjusted P values. 
 
Figure 5. Modular analysis of synovial and blood RNA-sequencing 
(A, B, C) Three axis polar plots of synovium (A) and blood (B) gene modules based on blood 
microarray modules (Li et al., 2014) and (C) synovium modules derived by weighted 
correlation network analysis (WGCNA), analysed using QuSAGE. Modules are colour-coded 
for statistical significance (FDR<0.05) for upregulation in different pathotypes. WGCNA 
synovium modules were annotated against single cell RNA-seq cell types (Stephenson et al., 
2018). (D) Heatmap showing gene expression in selected gene modules in synovium and 
blood, grouped by pathotype. (E) Boxplots of summarised module scores in synovium/blood. 
Statistical analysis by QuSAGE with FDR correction: *FDR<0.05, **FDR<0.01, 
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***FDR<0.001. (F) Comparison of number of significant (FDR<0.05) synovium/blood gene 
modules (Li et al) which correlate with clinical and radiographic markers of disease activity 
and response to 6 months treatment with DMARDs, in either synovium only (blue), blood 
only (red) or are concordantly correlated in both compartments (purple). Statistical analysis 
by Spearman correlation. (G) Bubble plot of –log10 P values comparing correlation of gene 
modules in synovium and blood with disease activity measured by DAS28-CRP, showing 
significantly (FDR<0.05) correlated modules found in synovium alone (blue), blood alone 
(red), or concordantly correlated with DAS28-CRP in both synovium and blood (purple). 
 
Figure 6. Baseline synovium plasma cell gene expression is associated with CCP 
antibody positivity and worse prognosis at 12 months 
(A, B) Differential gene expression in synovium RNA-seq comparing (A) anti-CCP antibody 
(ACPA) positive and ACPA negative RA individuals and (B) individuals with progression of 
bone erosions on x-rays at 12 months compared to baseline versus non-progressors. (C, D) 
Single cell RNA-seq-annotated WGCNA modular analysis shows that increased plasma cell 
module expression is associated with ACPA positivity and is predictive of bone erosion 
radiographic progression at 12 months. (E) Upstream regulator analysis using Ingenuity 
Pathway Analysis showing upstream regulator effects of cytokines and chemokines 
associated with ectopic lymphoid structure development in synovium. (F, G) Sankey 
diagrams showing change in histological pathotype following 6 months treatment with 
disease-modifying anti-rheumatic drugs (DMARDs) for (F) whole cohort or (G) grouped by 
ACPA status. Statistical analysis by Fisher test. (H) Shift in pathotype between baseline and 6 
months correlated against change in DAS28-ESR. Statistical analysis by Pearson correlation. 
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Figure 7. Association of RNA-seq modules and response to 6 months of DMARD 
treatment 
(A, B) Correlation of gene modules in synovium (x axis) vs blood (y axis) with 6 month 
response to DMARD treatment measured by (A) delta DAS28-CRP and (B) delta ESR. 
Significantly correlated synovial modules (at FDR<0.05) are shown in blue, significant blood 
modules in red, and modules, which concordantly correlate with each clinical parameter in 
both synovium and blood, are shown in purple. (C) Correlation of synovium gene modules 
with delta DAS28-CRP from baseline to 6 months. (D, E) Correlation of (D) synovium and 
(E) blood gene modules against change in ESR from baseline to 6 months following 
DMARD treatment. Statistical analysis by Spearman correlation with FDR adjustment (A-E). 
(F) Differential expression of synovial single cell-annotated WGCNA modules between 
EULAR DAS28-CRP responders (good/ moderate) and non-responders. Statistical analysis 
by QuSAGE with FDR adjustment. 
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SUPPLEMENTAL ITEMS 
Movie S1. Three-way volcano plot of synovial RNA-seq genes differentially expressed 
between histological pathotypes, related to Figure 3A 
 
Movie S2. Three-way volcano plot of blood RNA-seq genes differentially expressed 
between histological pathotypes, related to Figure 3B 
 
Table S4. Cell-lineage specific gene markers derived from FANTOM5, related to 
Figures 1B-D, 2 and S1 
See separate excel file filename Table S4.xlsx 
 
Table S5. Synovium gene modules derived by weighted gene correlation network 
analysis, related to Figure 5C 
See separate csv file filename Table S5.csv 
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STAR METHODS 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Costantino Pitzalis (c.pitzalis@qmul.ac.uk). This study did not 
generate new unique reagents. 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Pathobiology of Early Arthritis Cohort (PEAC) 
90 rheumatoid arthritis patients fulfilling 2010 ACR/EULAR RA Classification Criteria were 
enrolled at Barts Health NHS trust (London, UK) as part of the Medical Research Council 
(MRC) funded multi-centre Pathobiology of Early Arthritis Cohort (PEAC). The study 
received ethical approval from the UK Health Research Authority (REC 05/Q0703/198, 
National Research Ethics Service Committee London – Dulwich). All patients gave written 
informed consent. Patients had clinically defined synovitis, but duration of symptoms of less 
than 12 months. Patient characteristics are summarized in Supplementary Table S1. Exclusion 
criteria included all patients receiving corticosteroids, synthetic disease-modifying anti-
rheumatic drugs (sDMARDs) or biologic therapies. Upon enrolment and acquisition of 
demographic and clinical disease parameters, patients underwent minimally invasive 
ultrasound-guided synovial biopsy of a clinically active joint (see below). 
 
METHOD DETAILS 
Ultrasound-guided synovial biopsy 
We analysed 90 synovial samples acquired through a minimally invasive US-guided synovial 
biopsy (Kelly et al., 2015) from patients presenting with early RA naïve to therapy. 
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Ultrasonography scores were collected at the time of biopsy for both the individual biopsied 
joint as well as a global joint score. Immediately prior to baseline US-guided synovial biopsy 
standard longitudinal images of the 1st-5th metacarpo-phalangeal (MCP) joints and midline, 
radial and ulnar views of both wrist joints were acquired in addition to standard images of the 
joint undergoing US-guided synovial biopsy as previously described (Kelly et al., 2015). 
Images subsequently underwent semi-quantitative (SQ) assessment by a blinded assessor (IL) 
for both synovial thickening (ST) and power doppler activity (PD) according to standard 
EULAR-OMERACT US synovitis scores (grade 0-3) (Naredo et al., 2008). For each patient, 
baseline total mean (12max) ST (STUS) and PD (PDUS) scores were calculated by deriving 
the mean of the total scores for ST and PD for all 12 joints including maximal score in the 
wrist. STUS and PDUS were also recorded of the biopsied joint. All procedures were 
performed following written informed consent and were approved by the hospital’s ethics 
committee (REC 05/Q0703/198). 
 
Clinical assessments 
At baseline clinical parameters including CRP, ESR, RF/ACPA positivity/titre and DAS28 
were collected. Anonymised baseline radiographs of the hands and feet underwent scoring 
according to the modified Sharp van der Heijde scoring system by a trained reader. 
 
Synovial histology 
3µm paraffin embedded sections underwent standard H&E staining and then semi-quantitative 
assessment for degree of synovitis according to a previously validated score (Krenn et al., 
2006). In order to determine the degree of immune cell infiltration sequentially cut sections 
underwent staining for B cells (CD20), T cells (CD3), macrophages (CD68) and plasma cells 
(CD138) as previously reported (Humby et al., 2009), and mast cells (CD117). Sections 
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underwent SQ scoring (0-4) for CD3, CD20, CD68 lining (CD68L) and sublining (CD68SL) 
and CD138 number (Humby et al., 2009). CD20+ aggregates within synovial tissue were 
graded (1-3) according to a scoring atlas as previously described (Manzo et al., 2005). Synovial 
biopsies were categorized into 3 separate synovial pathotypes according to the following 
criteria: i) Lympho-myeloid (L) presence of grade 2-3 CD20+ aggregates, (CD20≥2) and/or 
CD138>2; ii) Diffuse-Myeloid (M) CD68SL≥2, CD20≤1 and/or CD3≥1, CD138≤2 and iii) 
pauci-immune Fibroid (F) CD68SL<2 and CD3, CD20, CD138<1. Automated image analysis 
and cell counting (cellSens, Olympus) was used to calculate the density of CD117+ mast cells 
(number/mm2). 
 
RNA extraction procedure 
All tissue samples were maintained on ice and homogenised in a fume hood using a rotor-stator 
benchtop laboratory homogeniser. Samples were homogenised at short five-second intervals 
until all the tissue had been sheared/homogenised. The probe of the homogeniser was cleaned 
thoroughly in between samples by washing initially in RNase Away solution (Fisher Scientific, 
UK), followed by four washes in sterile/RNase-free water (Baxter Healthcare Ltd, UK). RNA 
was extracted from a minimum of 10mg of synovial tissue homogenised at 4°C in Trizol 
reagent (ThermoFisher Scientific, Invitrogen Division, UK). Chloroform was mixed with the 
lysate and following centrifugation the aqueous RNA layer was transferred to a new 
microcentrifuge tube. Isopropanol at 4°C was mixed with the RNA layer. Following incubation 
and centrifugation, the isopropanol was removed and the RNA pellet washed with 70% ethanol. 
The pellet was re-dissolved in RNase-free water. 
Whole blood samples were preserved in RNALater solution (ThermoFisher Scientific, 
UK) (500µL wholeblood: 1.3mL RNALater solution) and stored at -80°C prior to extraction. 
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Blood samples in RNALater solution were thawed on ice and RNA prepared using the Ambion 
Ribo-Pure Blood kit (ThermoFisher Scientific, UK), as per the manufacturer’s instructions. 
The concentration/purity of RNA samples was measured using the NanoDrop 2000C 
(Lab Tech, UK) and RNA quality (RIN) was assessed by Agilent 2100 Bioanalyser (Agilent 
Technologies, UK) and 2200 TapeStation (Agilent Technologies). 
 
RNA sequencing 
Where available, 1µg of total RNA was used as an input material for library preparation using 
TruSeq RNA Sample Preparation Kit v2 (Illumina). Generated libraries were amplified with 
10 cycles of PCR. Size of the libraries was confirmed using 2200 TapeStation and High 
Sensitivity D1K screen tape (Agilent Technologies) and their concentration was determined by 
qPCR based method using Library quantification kit (KAPA). The libraries were first 
multiplexed (five per lane) and then sequenced on Illumina HiSeq2500 (Illumina) to generate 
50 million of paired end 75 base pair reads (154 samples) or 30 million of single end 50 base 
pair reads (10 samples). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
RNA-sequencing data processing 
Transcript abundance was derived from paired (154 samples) or single (10 samples) FASTQ 
files over GENCODE v24/GRCh38 transcripts using Kallisto v0.43.0 (Bray et al., 2016).  
Transcript abundances and average transcript lengths were imported into R using Bioconductor 
package tximport 1.4.0 and summarised over NCBI RefSeq transcript isoforms. Imported 
abundances were normalised in R, including a correction for average transcript length and 
incorporating batch, sex, and pathotype as model covariates, using DESeq2 1.14.1 (Love et al., 
2014). Transcript abundances underwent regularised log expression (RLE) transformation. 
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Principal components analysis (PCA) was performed on the RLE normalised data and paired 
plots of first 10 eigenvectors were generated to identify outliers. After removal of three 
synovium RNA sample outliers, transcript abundances for the remaining synovium (n=87) and 
blood (n=67) samples were re-imported into R, normalised, and underwent RLE transformation 
followed by PCA again to confirm homogeneity of each dataset. 
 
Identification of cell-specific gene sets 
RLE normalised FANTOM5 data were downloaded from http://fantom.gsc.riken.jp/5/data/. 
Data were subsetted to include only unmanipulated and uncultured primary tissues (derived 
cells, stimulated cells and cell lines were excluded) and restricted to NCBI gene transcripts. 
For each gene only the CAGE peak with the highest mean expression was used. Data were Z 
score normalised across all primary tissues and expression of each gene ranked across all 
tissues. A specificity score was determined for all genes by counting the number of tissues 
showing increased gene expression Z score >3 (i.e. more than 3 SD above the mean expression 
across all tissues), so that the most tissue specific genes would have the lowest specificity 
scores. After different cut-offs were tested for robustness, genes were considered specific to a 
tissue type using the following criteria: i) the level of gene expression in that tissue was in the 
top three tissues (i.e. rank 1-3); ii) Z score > 5 (i.e. >5 SD above the mean expression across 
all tissues); iii) specificity score <10 tissues. Gene modules for different cell types were 
consistent with lists of genes previously published by the FANTOM5 consortium for several 
cell types (Motakis et al., 2014; Schmidl et al., 2014). 
 
Gene module scoring 
Gene module scores for synovial RNA-seq data were derived by singular value decomposition 
(SVD) for each gene module matrix using methodology described in detail by other studies 
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(Langfelder and Horvath, 2007). Module scores specific for B cells, T cell subsets, 
monocyte/macrophage subsets, plasma cells and mast cells were analysed for correlation 
against relevant histological markers in synovial tissue. Statistical comparison of groups was 
performed using one-way ANOVA and post-hoc Bonferroni test. 
 
Differential expression analysis 
Differential Expression analysis based on negative binomial distribution using regression 
models of normalised count data was performed using DESeq2 using a likelihood ratio test to 
compare variation between pathotype groups in synovium and peripheral blood RNAseq 
samples, followed by pairwise comparisons between Lympho-myeloid, Diffuse-Myeloid and 
pauci-immune Fibroid groups. P values were converted to Q values based on Benjamini-
Hochberg false discovery rate (FDR), using FDR cut-off set at Q<0.05 to define differentially 
expressed genes. MA and volcano plots were generated to illustrate the distribution of 
significant genes in each comparison.  
 
3D volcano plot 
Three-way differential expression was visualised by a 3D cylindrical volcano plot using R 
package plotly 4.6.0. RLE counts were Z-score normalised and mean Z scores calculated for 
the three pathotype groups (L, M, F) for each gene. This three dimensional data were reduced 
to two dimensional polar coordinate system analogous to colour space conversion of red, green, 
blue (RGB) colour space to hue, saturation, value (HSV): 
 ! = 	 √%	& 	(( − *) 
 , = - − .& (( + *) 
 0 = 12132	(,, !) 
 6 = 7!& + ,& 
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Thus Lympho-myeloid, Diffuse-Myeloid, pauci-immune Fibroid vectors were mapped to three 
axes in the horizontal plane (see polar plots Figure 2B, C). Fold change can be used as an 
alternative to Z score for the radial scale without affecting θ. z axis shows –log10 P value for 
likelihood ratio test comparing all three groups. Genes with FDR-adjusted P value for 
likelihood ratio test <0.05 were considered significant. Significant genes were colour-coded 
based on pairwise statistical tests using the minimum group mean as reference. Genes which 
were significantly upregulated in one group alone were coloured using primary colours, i.e. 
Lympho-myeloid, blue; Diffuse-Myeloid, red; and pauci-immune Fibroid, green. Genes 
upregulated in two groups compared to the minimum reference group were depicted using 
secondary colours i.e. genes upregulated in Lympho-myeloid and Diffuse-Myeloid compared 
to pauci-immune Fibroid: purple; upregulated in Diffuse-Myeloid and pauci-immune Fibroid 
vs Lympho-myeloid: yellow; upregulated in Lympho-myeloid and pauci-immune Fibroid vs 
Diffuse-Myeloid: cyan. Non-significant genes are coloured grey. 
 
Hierarchical clustering 
Hierarchical clustering on 2964 differentially expressed synovium genes (FDR<0.05, log2 fold 
change >1) and 548 blood genes with evidence of differential expression (FDR<0.15) was 
performed using Euclidean distance metric and Ward’s linkage method and plotted using the 
ComplexHeatmap package 1.14.0 in R. Colour tracks for histology data for CD3, CD20, 
CD68L/SL, CD138 and overall pathotype were included to aid interpretation. 
 
Pathway Analysis 
Pathway analysis was performed for each of four clusters of genes which were identified via 
hierarchical clustering by gene enrichment analysis using Ingenuity Pathway Analysis (IPA, 
QIAGEN, Redwood City, CA, USA). Upstream regulators were identified for pathotypes and 
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gene clusters. All P values were FDR adjusted. Pathway analysis was undirected and detected 
enrichment against a background of all human genes. 
 
Modular gene analysis 
RNA-seq read counts were analysed for differential gene module expression, using the 
Bioconductor package Quantitative Set Analysis for Gene Expression (QuSAGE, version 
2.10.0) (Yaari et al., 2013), using gene modules derived from Li et al (2014). Where stated, P 
values were corrected for multiple testing using Storey’s q value. Weighted correlation network 
analysis (WGCNA) on synovium RNA-seq was performed using R package WGCNA 
(Langfelder and Horvath, 2007). Gene modules were annotated against 13 cell types identified 
by single cell RNA-seq of RA synovium (Stephenson et al., 2018), using enrichment testing 
by hypergeometric test for module genes differentially upregulated in each single cell RNA-
seq cell type. Modules were also annotated for pathways using REACTOME and Kegg 
databases. 
 
DATA AND SOFTWARE AVAILABILITY 
The RNA-Seq data have been deposited in ArrayExpress under Accession code E-MTAB-
6141. 
 
ADDITIONAL RESOURCES 
Web interface 
To facilitate data exploration, we developed a web interface available at 
http://peac.hpc.qmul.ac.uk/. The website was constructed using R shiny server 1.5.2 with 
interactive plots generated using R plotly 4.7.1. This allows interactive 3D visualisation of the 
three-way volcano plot allowing users to click on individual genes to see their expression. A 
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searchable interface is available to examine relationships between individual synovial and 
blood gene transcript levels and histological, clinical and radiographic parameters, and clinical 
response at 6 months. A selectable table of synovial genes differentially expressed in different 
pathotypes is included. An interactive interface allows the gene module analysis to be explored 
for relationships between modules and clinical parameters. Figure S4 summarises the main 
features of the website. 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
CD20cy, L26, Unconjugated, Culture 
supernatant Agilent Technologies 
Dako Cat# M0755 
RRID:AB_2282030 
CD3, F7.2.38, Unconjugated, Culture 
supernatant Agilent Technologies 
Agilent Technologies 
Cat# M7254 
RRID:AB_2631163 
CD68, KP1, Unconjugated, Culture supernatant Agilent Technologies Dako Cat# M0814 RRID:AB_2314148 
CD138, MI15, Unconjugated, Culture 
supernatant Agilent Technologies 
Dako Cat# M7228 
RRID:AB_2254116 
CD21, 1F8, Unconjugated, Culture supernatant Agilent Technologies Dako Cat# M0784 RRID:AB_2085307 
Chemicals, Peptides, and Recombinant Proteins 
TRIzol® Reagent ThermoFisher Scientific/Invitrogen Division 15596018 
Xylene Mixt. of Isomers ANALAR ACS/R.PE - 
Analytical Grade VWR International 28975.325 
Eosin Yellowish VWR International 341973R 
Haemotoxylin Sigma-Aldrich H-3136 
Deposited Data 
FANTOM5 CAGE seq data (Fantom Consortium et al., 
2014) 
http://fantom.gsc.rike
n.jp/ 
RNA-seq on synovium and blood in rheumatoid 
arthritis 
This paper ArrayExpress E-
MTAB-6141 
Software and Algorithms 
R statistics R foundation https://www.r-
project.org/ 
Kallisto (Bray et al., 2016) https://pachterlab.git
hub.io/kallisto/ 
tximport Bioconductor https://www.biocond
uctor.org/packages/r
elease/bioc/html/txim
port.html 
DESeq2 (Love et al., 2014) https://www.biocond
uctor.org/packages/r
elease/bioc/html/DE
Seq2.html 
shiny RStudio https://shiny.rstudio.
com/ 
plotly.r Plotly https://plot.ly/r/ 
ComplexHeatmap Bioconductor https://www.biocond
uctor.org/packages/r
elease/bioc/html/Co
mplexHeatmap.html 
Ingenuity Pathway Analysis Qiagen Bioinformatics http://www.qiagenbio
informatics.com/IPA 
QuSAGE (Yaari et al., 2013) https://www.biocond
uctor.org/packages/r
elease/bioc/html/qus
age.html 
WGCNA (Langfelder and Horvath, 
2007) 
https://cran.r-
project.org/web/pack
ages/WGCNA/index.
html 
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Cytoscape Cytoscape Consortium http://www.cytoscap
e.org/ 
PEAC RNA-seq web interface This paper http://peac.hpc.qmul.
ac.uk/ 
Other 
Target Retrieval Solution, x10 Concentrate Agilent Technologies S1699 
DAB+, Liquid, 2-component system Agilent Technologies K3468 
Peroxidase-Blocking Solution, Dako REAL Agilent Technologies S2023 
Protein Block, Serum-Free, Liquid form, Agilent Technologies X0909 
Antibody Diluent, Background Reducing Agilent Technologies S3022 
EnVision+ Single Reagents, HRP. Mouse Agilent Technologies K4001 
Proteinase K Agilent Technologies S3020 
RNA 6000 Nano Kit Agilent Technologies 5067-1511 
Microscope slides; Superfrost Plus Fisher Scientific 10149870 
Microtome blades MX35 Premier (34°/80mm) Fisher Scientific 3051835 
RNase Away Solution Fisher Scientific 10666421 
RNALater Solution ThermoFisher Scientific/Ambion Division AM7021 
Sterile Water, RNAse-free Baxter Healthcare UKF7114 
Fibrowax (pastillated) VWR International 361427G 
Cover Glass 22x64mm VWR International 631-0880 
DePex Mountant VWR International 360294H 
Ambion Ribo-Pure Blood kit ThermoFisher 
Scientific/Ambion Division 
AM1928 
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CBlood M16: TLR and
Inflammatory signalling
M75: antiviral IFN signature
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M17.2: Hox cluster III
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M86.0: chemokines/infllammatory
molecules in myeloid cells
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M16: TLR and inflammatory
signalling
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Molecular portraits of early rheumatoid arthritis identify clinical and treatment response 
phenotypes 
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Table S1. Baseline demographics of treatment naïve individuals with early rheumatoid arthritis, 
related to Figure 1 
 
 Whole 
cohort 
Lympho-
myeloid 
Diffuse 
Myeloid 
Pauci-
immune 
fibroid 
Ungraded P value 
n 90 45 20 16 6  
Age (years) 54 ± 17 53 ± 2.4 51 ± 4.1 55 ± 3.9 47 ± 5.0 0.76 
Sex female:male 64:23 
(74%:26%) 
34:11 14:6 12:4 4:2 0.94 
Disease duration 
(months) 
5.6 ± 3.2 6.3 ± 0.46 4.8 ± 0.79 6.1 ± 0.80 5.4 ± 1.4 0.25 
RF positive (%) 62 (71%) 32 (71%) 14 (70%) 12 (75%) 3 (50%) 1.0 
CCP positive (%) 64 (74%) 35 (78%) 13 (65%) 12 (75%) 4 (66%) 0.58 
DAS28 5.8 ± 1.3 6.3 ± 0.19 5.55 ± 0.25 5.48 ± 0.41 6.40 ± 0.54 0.051 
ESR (mm/hr) 44 ± 29 54 ± 4.4 36 ± 5.5 35 ± 7.8 33 ± 7.3 0.026 
CRP (µg/mL) 23 ± 33 26 ± 4.0 17 ± 5.5 25 ± 13.8 7 ± 2.9 0.45 
TJC 12 ± 7.6 13 ± 1.1 9.6 ± 1.4 12 ± 2.3 17 ± 3.3 0.20 
SJC 7.9 ± 5.7 8.8 ± 0.87 6.8 ± 0.93 6.6 ± 1.7 9.2 ± 2.7 0.26 
VAS 63 ± 24 67 ± 3.6 63 ± 5.0 59 ± 6.5 78 ± 6.5 0.56 
HAQ 1.54 ± 0.76 1.63 ± 0.12 1.37 ± 0.12 1.59 ± 0.21 1.50 ± 0.39 0.31 
US Synovial 
thickness (12max) 
16.7 ± 9.1 17.0 ± 1.5 14.9 ± 1.9 17.7 ± 2.1 14.0 ± NA 0.67 
US Power Doppler 
(12max) 
7.0 ± 6.2 8.0 ± 0.99 5.9 ± 1.1 5.9 ± 1.6 3.0 ± NA 0.42 
x-ray SvH score 3.7 ± 8.0 4.5 ± 1.5 1.5 ± 0.57 3.5 ± 1.3 3.0 ± 2.1 0.14 
Data for whole cohort expressed as mean ± SD. Data for pathotype groups expressed as mean ± SEM. 
Statistical analysis for difference between pathotype groups (excluding ungraded) and continuous variables 
calculated by one-way ANOVA and categorical variables by Fisher exact test. 
 
Abbreviations: RF: rheumatoid factor; CCP: cyclic citrullinated peptide antibody; DAS28: 28-joint disease 
activity score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TJC: tender joint count; SJC: 
swollen joint count; HAQ: health assessment questionnaire score; US: ultrasound; SvH: Sharp van der 
Heijde score. 
 
Table S2. Distribution of synovial pathotypes, related to Figure 1 
 Lymphoid Myeloid Fibroid Ungraded 
n (synovium RNA 
pre-QC) 
46 (51%) 21 (23%) 17 (19%) 6 (7%) 
n (synovium RNA 
post-QC) 
45 (52%) 20 (23%) 16 (18%) 6 (7%) 
n (blood RNA 
pre/post-QC) 
30 (45%) 13 (19%) 16 (24%) 8 (12%) 
  
3 
 
Table S3. Demographics of disease modifying anti-rheumatic drug (DMARD) therapy at 6 
months, related to Figures 6F-H & 7 
MTX/SZP 65 (55%) 
MTX/HCQ 22 (19%) 
MTX/SZP/HCQ 8 (6.8%) 
MTX alone 8 (6.8%) 
HCQ alone 7 (5.9%) 
SZP alone 4 (3.4%) 
None 3 (2.5%) 
 
Abbreviations: MTX: methotrexate; SZP: sulfasalazine; HCQ: hydroxychloroquine. 
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Figure S1. Heatmap of FANTOM5 CAGE sequencing gene expression for cell-specific 
immune cell genes, related to Figure 1 & 2 
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Figure S2. Correlation plot of clinical parameters against synovial histology scores, related to 
Figure 2 
Numerical values represent Spearman rho values. *P<0.05, **P<0.01, ***P<0.001. 
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Figure S3. Conventional volcano plots of pairwise differential gene expression in rheumatoid arthritis 
RNA-sequencing of synovium and peripheral blood, related to Figure 3A,B 
Volcano plots of pairwise comparisons of differentially expressed genes (red) between the three histological 
groups (Lymph-myeloid, Diffuse Myeloid and pauci-immune Fibroid) by RNA-sequencing of (A) synovial tissue 
or (B) whole blood in early rheumatoid arthritis. Statistical analysis by DESeq2 likelihood ratio test. Horizontal 
dotted line represents FDR<0.05.  
BA
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Figure S4. PEAC RNA-seq web interface, related to Figure 5 & 7  
Summary of main features of PEAC RNA-seq web interface (http://peac.hpc.qmul.ac.uk/) allowing users to explore the 
data analysis using interactive plots and tables and searchable interface for genes and modules. 
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Figure S5. Modular analysis of synovial and blood RNA-sequencing, related to Figure 5A,B 
Synovium and blood gene module plots based on blood microarray modules (Li et al, 2014), analysed using QuSAGE. 
Significant modules FDR-corrected P<0.01 are shown for paired comparisons of Lymphoid, Myeloid and Fibroid 
samples in (A) synovium and (B) peripheral blood. Top 15 most statistically significant modules are shown for each 
paired comparison. FDR-corrected P values shown by green colour scale. 
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Figure S6. Correlation of histological, clinical and radiographic data with selected single cell RNA-seq annotated 
WGCNA modules and blood modules, related to Figure 5C 
See website (http://peac.hpc.qmul.ac.uk/) to browse full correlation data for all modules and all variables, under the 
Modules tab. 
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Figure S7. Blood RNA-seq differentially gene expression in anti-CCP antibody positive versus negative RA 
individuals, related to Figure 6A 
Differentially expressed genes in blood RNA-seq showing upregulated interferon response genes in anti-CCP antibody 
(ACPA) positive RA individuals compared to ACPA negative individuals at FDR<0.10. 
 
